Core Viewpoint - Bailong Chuangyuan (605016.SH) announced a public offering of convertible bonds to raise a total of no more than RMB 748 million, which will be fully invested in specific projects after deducting related issuance costs [1] Group 1 - The funds raised will be allocated to the Thailand Health New Food Raw Material Smart Factory Project [1] - The funds will also support the functional sugar drying expansion and comprehensive improvement project [1]

Group 1 - The company, Bailong Chuangyuan (605016.SH), announced plans to issue convertible bonds to unspecified investors, aiming to raise a total of no more than 748 million yuan, including the principal amount [1] - The raised funds, after deducting related issuance costs, are intended to be fully invested in two projects: a smart factory project for new health food raw materials in Thailand and an expansion and comprehensive enhancement project for functional sugar drying [1]

Core Viewpoint - Bailong Chuangyuan (605016.SH) announced a public offering of convertible bonds to raise a total of up to RMB 748 million, which will be fully invested in specific projects after deducting related issuance costs [1] Group 1 - The total amount raised from the issuance of convertible bonds is capped at RMB 748 million [1] - The funds will be allocated to the Thailand health food raw material smart factory project and the functional sugar drying expansion and comprehensive improvement project [1]

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing a decline in stock price while benefiting from its unique product offerings and strategic investments, particularly in the context of the depreciating RMB and its recognition as a "specialized and innovative" enterprise. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotics, dietary fiber products, and healthy sweeteners, with a revenue composition of 54.15% from dietary fiber, 28.00% from prebiotics, 13.57% from healthy sweeteners, and 3.91% from other products [8] - As of November 30, the company had 10,900 shareholders, a decrease of 18.48% from the previous period, with an average of 38,364 circulating shares per shareholder, an increase of 22.67% [8] - The company achieved a revenue of 969 million yuan in the first nine months of 2025, representing a year-on-year growth of 18.10%, and a net profit of 265 million yuan, up 44.93% year-on-year [8] Group 2: Market Position and Financials - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which may provide additional financial stability [3] - The overseas revenue accounts for 60.62% of total revenue, benefiting from the depreciation of the RMB [4] - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9] Group 3: Investment Highlights - The company produces allulose, a rare monosaccharide that serves as a low-calorie alternative to sucrose, making it ideal for individuals with obesity and diabetes [2] - The company has been recognized as a "specialized and innovative" enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong market focus and innovation capabilities [4] - The stock has seen a recent decline of 2.01% with a trading volume of 48.91 million yuan and a market capitalization of 8.61 billion yuan [1]

Group 1 - The company, Bailong Chuangyuan, reported that as of November 30, 2025, the total number of shareholders is 10,948 [2]

Core Points - The company held its fourth extraordinary general meeting of shareholders on December 1, 2025, with no resolutions being rejected [2][3] - The meeting was convened by the board of directors and chaired by Chairman Dou Baode, utilizing a combination of on-site and online voting methods [2][3] - A special resolution regarding the company's previous fundraising usage report was approved, requiring more than two-thirds of the voting rights held by attending shareholders [3][5] Meeting Details - The meeting took place at the company's office building in Yucheng, Dezhou, Shandong Province [2] - All seven current directors attended the meeting, along with the board secretary and other senior executives [4] - The meeting's legal compliance was confirmed by Beijing Hairun Tianrui Law Firm, ensuring that all procedures and voting were in accordance with the Company Law and relevant regulations [5][6]

证券代码：605016 证券简称：百龙创园 公告编号：2025-073 山东百龙创园生物科技股份有限公司 2025年第四次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 12 月 1 日 (二)股东会召开的地点：山东省德州市禹城市高新技术开发区德信大街百龙创园 公司办公楼一楼第二会议室 络投票相结合的方式进行表决。本次股东会的召集、召开以及表决方式符合《公 司法》、《公司章程》及相关法律、法规的规定。 (五)公司董事和董事会秘书的出席情况 1、公司在任董事7人，出席7人； (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 132 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 218,042,031 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 51.9132 | | 份总数的比例（ ...

中国·北京 北京海润天睿律师事务所 北京市朝阳区建外大街甲 14 号广播大厦 5&9&10&13&17 层 邮编:100022 电话：(010)65219696 传真：（010）88381869 2025 年第四次临时股东会的法律意见书 关于山东百龙创园生物科技股份有限公司 法律意见书 北京海润天睿律师事务所 关于山东百龙创园生物科技股份有限公司 2025 年第四次临时股东会的法律意见书 致：山东百龙创园生物科技股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受山东百龙创园生物科技 股份有限公司（以下简称"公司"）的委托，指派律师潘仙、张阳出席公司 2025 年第四次临时股东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"） 等法律法规、规范性文件及《山东百龙创园生物科技股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，对本次股东会相关事项依法进行见证并发 表法律意见。 为出具本法律意见书，本所律师出席了公司本次股东会，审查了公司提供的 召开本次股东会的有关文件。公司已向本所及本所律师承诺，其所提供的文件和 所作的陈述、说明是完整、真实和有效的，无任何隐瞒、遗漏，并据此出具法律 ...

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing positive market movements, with a recent stock price increase and significant revenue growth, driven by its innovative health sweetener products and strategic investments in the banking sector [1][2][4]. Company Overview - Shandong Bailong Chuangyuan Biotechnology Co., Ltd. was established on December 30, 2005, and went public on April 21, 2021. The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners [8]. - The company's main business revenue composition includes dietary fiber series (54.15%), prebiotic series (28.00%), health sweeteners (13.57%), and others (3.91%) [8]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 969 million yuan, representing a year-on-year growth of 18.10%. The net profit attributable to the parent company was 265 million yuan, with a year-on-year increase of 44.93% [8]. - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. Market Position and Strategic Advantages - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which positions it favorably within the financial sector [3]. - The company benefits from a 60.62% share of overseas revenue, aided by the depreciation of the Chinese yuan [4]. - It has been recognized as a "specialized, refined, characteristic, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [4]. Stock Market Activity - The stock price of Bailong Chuangyuan increased by 2.61%, with a trading volume of 126 million yuan and a turnover rate of 1.42%, leading to a total market capitalization of 8.904 billion yuan [1]. - The stock has shown a slight net outflow of 22.4583 million yuan from major investors, indicating a lack of strong buying momentum [5][6].

Core Viewpoint - The company, Shandong Bailong Chuangyuan Biotechnology Co., Ltd., is experiencing growth in its health sweetener products, particularly allulose, which is beneficial for obesity and diabetes patients. The company is also benefiting from its stake in a rural commercial bank and the depreciation of the RMB, while being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Overview - The company specializes in the research, production, and sales of prebiotic series products, dietary fiber series products, and health sweeteners, with revenue contributions of 54.15% from dietary fiber, 28.00% from prebiotics, and 13.57% from health sweeteners [8]. - As of October 31, the company had 13,400 shareholders, with an average of 31,274 circulating shares per person, reflecting a 3.62% decrease [8]. - The company reported a revenue of 969 million yuan for the period from January to September 2025, representing an 18.10% year-on-year growth, and a net profit of 265 million yuan, which is a 44.93% increase year-on-year [8]. Group 2: Financial Performance - The company has distributed a total of 183 million yuan in dividends since its A-share listing, with 172 million yuan distributed over the past three years [9]. - The average trading cost of the company's shares is 20.58 yuan, with the current stock price near a support level of 20.53 yuan [7]. - The company’s market capitalization is 8.677 billion yuan, with a trading volume of 40.56 million yuan and a turnover rate of 0.47% on November 27 [1]. Group 3: Market Position and Recognition - The company holds a 5.14% stake in Shandong Yucheng Rural Commercial Bank, which contributes to its financial stability [3]. - The company is recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitiveness and stability within the industry [4]. - The company’s overseas revenue accounts for 60.62% of its total revenue, benefiting from the depreciation of the RMB [4].